EMA/359497/2023

15 December 2023

Human Medicines Division

Report to the European Commission

on companies and products that have benefited from any of the rewards andincentives in the Paediatric Regulation[1] and on the companies that have failed to comply with any of the obligations in this regulation

Year 2022

Prepared by: Paediatric Medicines Office
Scientific Evidence Generation
DepartmentEuropean Medicines Agency

[1] REGULATION (EC) No 1901/2006 of the EUROPEAN PARLIAMENT AND OF THE COUNCIL on medicinal products for paediatric use (Regulation (EC) No 1901/2006 and Regulation (EC) No 1902/2006)

Table of contents

Acronyms, abbreviations

CHMP	Committee for Medicinal Products for Human Use
EC	European Commission
EMA, the Agency	European Medicines Agency
INN	International non-proprietary name
MA	Marketing authorisation
MAH	Marketing authorisation holder(s)
MS	Member States
NCA	National Competent Authorities
NPO	National Patent Offices
PA	Protocol assistance
Paediatric Regulation	REGULATION (EC) No 1901/2006 of the EUROPEAN PARLIAMENT AND OF THE COUNCIL on medicinal products for paediatric use
PDCO	Paediatric Committee
PIP	Paediatric investigation plan
PUMA	Paediatric use marketing authorisation
SA	CHMP Scientific Advice
SAWP	Scientific Advice Working Party
SPC	Supplementary protection certificate

1. Introduction

1.1. Scope of the report

REGULATION (EC) No 1901/2006 of the European Parliament and of the Council on medicinal products for paediatric use (Paediatric Regulation) entered into force on 26 January 2007.

Article 50(1) states:

"On the basis of a report from the Agency, and at least on an annual basis, the Commission shall make public a list of the companies and of the products that have benefited from any of the rewards and incentives in this Regulation and the companies that have failed to comply with any of the obligations in this Regulation. The Member States shall provide this information to the Agency."

This report covers year 2022 and lists the companies benefiting from and infringing the regulation.

1.2. Data collection and methodology

In December 2022 the Agency contacted the national patent offices (NPO) of each Member State (MS) with regard to the medicinal products that had obtained a six-month extension of the supplementary protection certificate (SPC) in 2022.

The Agency received contributions from the following Member State NPOs: Austria, Belgium, Bulgaria, the Czech Republic, Cyprus, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain and Sweden.

Between July 2023 and September 2023, companies identified as potentially infringing the Paediatric Regulation in 2022 with regard to non-completion of a paediatric investigation plan (PIP) by the agreed date and non- submission of an annual report on deferred measures by the due date, were given an opportunity to provide comments on the finding before publication of the identified infringement. All information received by 12 September 2023 was considered for finalisation of this report.

2. Companies and products that have benefited from therewards and incentives in the regulation

2.1. Scientific advice or protocol assistance from the EMA

In accordance with Article 26 of the Paediatric Regulation, the Agency provides free scientific advice (SA) or protocol assistance (PA) on any question related to paediatric development of a medicinal product. The advice is prepared by the Scientific Advice Working Party (SAWP) and is adopted by the Committee for Medicinal Products for Human Use (CHMP). For the requests on paediatric development, members of the Paediatric Committee (PDCO) routinely contribute as experts to the provision of scientific advice through the SA/PA procedures (Figure 1).

The number of SA/PA procedures including paediatric questions (paediatric only advice and advice concerning adult and paediatric medicines development) in 2022 is overall in the range of the years before 2021. PDCO members are involved in procedures relating to paediatric development as well as in procedures that do not directly include paediatric questions but where paediatric development could be affected.

Figure 1. Scientific advice and protocol assistance, incl. follow-ups (by the EMA, SAWP and CHMP, p/a 2009-2022)



Source EMA databases. *from 2017: includes also parallel consultation with regulators and health technology assessment

2.2. Rewards

2.2.1. Extensions of the supplementary protection certificate

Extensions of the supplementary protection certificate (SPC) are granted by National Patent Offices (NPO) therefore the data provided in this report relies on the information provided by these offices. This report provides data only for SPC extensions that have been granted, unlike in years prior to 2015 when pending SPC extensions were also reported. Furthermore, products may be mentioned in annual reports of several years because SPC expiration (and therefore extension) may not be simultaneous in all EU countries, and hence a product may obtain SPC extension in different years in the various countries. In 2022, 44 active substances including fixed-dosed combinations (FDC) benefited from the six-month extension (see Table 1).

Table 1. List of companies / products receiving six-month SPC extension in 2022

Company / SPC holder	**Substance (INN as applicable)**	**SPC extension granted in 2022**
AbbVie Bahamas Ltd	glecaprevir / pibrentasvir	Cyprus
AbbVie Bahamas Ltd.(FR, FI, HU, IR, SK); AbbVie Ireland Unlimited Company (BU, EE, GR); AbbVie Deutschland GmbH & Co. KG (ES)	pibrentasvir	Bulgaria Estonia Finland France Greece Hungary Ireland Slovakia Spain
Amgen Inc. (BU, CZ, LT); Immunex Coorporation(DK); Daiichi Sankyo Company, limited (HU)	denosumab	Bulgaria Czech Republic Denmark Hungary Lithuania
Amgen K-A, Inc; Kirin-Amgen Inc (LV, NL)	romiplostim	Austria Belgium Finland Ireland Italy Latvia

		Lithuania Netherlands Portugal Romania Slovenia
Astellas Pharma Inc, Astellas Pharma & Wakanuga Pharmaceutical (NL)	ceftolozane	Austria Netherlands
AstraZeneca AB	dapagliflozin	Bulgaria Czech Republic Estonia Germany Latvia Malta Netherlands Portugal Slovenia
AstraZeneca AB; AstraZeneca UK Limited (EE)	ticagrelor	Bulgaria Cyprus Czech Republic Estonia Finland France Germany Hungary Ireland Italy Latvia Lithuania Netherlands Poland Portugal Romania

		Slovenia Spain Sweden
Bayer Healthcare LLC;	damoctocog alfa pegol	Finland Hungary Poland
Bayer Intellectual Property GmbH; Bavar intellectual property (RO); Bayer AG (ES)	rivaroxaban	Belgium Cyprus France Poland Romania Spain
Enanta Pharmaceuticals, Inc; AbbVie Deutschland GmbH & Co. KG (ES)	glecaprevir	Bulgaria Czech Republic Estonia Finland France Greece Hungary Ireland Spain
Enanta Pharmaceuticals, Inc	glecaprevir / pibrentasvir	Cyprus
Exelixis, Inc.	cobimetinib	Austria Bulgaria
Boehringer Ingelheim Pharma GmbH & Co. KG; Boehringer Ingelheim International GmbH (ES)	afatinib	Bulgaria Cyprus Czech Republic Estonia Finland Germany Hungary Italy

		Latvia Lithuania Netherlands Portugal Romania Slovakia Slovenia Spain Sweden
Boehringer Ingelheim Pharma GmbH & Co. KG	dabigatran etexilate	Bulgaria Poland
Boehringer Ingelheim Pharma GmbH & Co. KG (LV); Boehringer Ingelheim International GmbH	idarucizumab	Bulgaria Cyprus Czech Republic Estonia Finland Italy Latvia Netherlands Portugal Slovenia
Chiesi Farmaceutici S.p.A.	beclomethazone / formoterol	Italy
Eisai R&D Management Co. Ltd ; Eisai GmbH (ES)	eribulin	Austria Cyprus Finland Hungary Ireland Italy Netherlands Portugal Spain
Gilead Pharmasset LLC	ledipasvir	Bulgaria

Gilead Pharmasset LLC	sofosbuvir	Bulgaria Czech Republic France Greece Ireland Poland Slovakia
Gilead Sciences International Limited	elvitegravir	Spain
GlaxoSmithKline Biologicals SA	HPV L1 VLPs 16 + 18 + 31	Lithuania Netherlands
GlaxoSmithKline Biologicals SA	HPV L1 VLPs 16 + 18 + 45	Lithuania Netherlands
GlaxoSmithKline Biologicals SA	HPV L1 VLPs 16, 18 and 52	Netherlands
Janssen Biotech, Inc.	golimumab	Sweden
Janssen Biotech, Inc.	ustekinumab	Belgium Germany Poland
Janssen Pharmaceutica N.V.;	etravirine	Belgium Estonia France Portugal
Japan Tobacco, Inc.	elvitegravir	Austria Bulgaria Finland Hungary Lithuania Netherlands Portugal Romania Slovakia Slovenia

Japan Tobacco, Inc	Elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil	Cyprus Estonia Germany Italy Latvia Malta
Merck Sharp & Dohme BV; Merck Sharp & Dohme Limited (ES)	pembrolizumab	Bulgaria Cyprus Estonia Finland France Germany Greece Hungary Latvia Lithuania Malta Romania Slovakia Spain Sweden
Merck Sharp & Dohme Corp.;	fidaxomicin	Belgium Romania
Merck Sharp & Dohme LLC	HPV 31 L1 protein	Netherlands
Merck Sharp & Dohme LLC	HPV 58 L1 protein	Netherlands
Merck Sharp & Dohme LLC	HPV 45 L1 protein	Netherlands
Merck Sharp & Dohme LLC	HPV 52 L1 protein	Netherlands
Novartis AG; Novartis Europharm Limited (ES)	pazopanib	Cyprus Czech Republic Finland France Germany Hungary

		Ireland Italy Poland Portugal Slovenia Spain Sweden
Novartis AG	secukinumab	Austria Bulgaria Czech Republic Estonia Finland Germany Hungary Italy Latvia Lithuania Netherlands Portugal Romania Slovakia Slovenia
Novo Nordisk A/S	liraglutide	Denmark Germany
N.V. Organon	corifollitropin alfa	Finland Germany Hungary Italy Portugal
Pharming Intellectual Property BV	conestat alfa	Germany

Phivco-1 LLC; Phivco UK Limited (CY)	maraviroc	Cyprus Denmark Slovakia
Royalty Pharma Collection Trust.	alogliptin	Denmark
Royalty Pharma Collection Trust.	linagliptin	Denmark
Royalty Pharma Collection Trust.	saxagliptin	Denmark
Takeda Pharmaceutical Company Limited	phosphonocephem	Belgium
Theramex HQ UK Ltd	nomegestrol acetate / estradiol	Denmark

Source: NPO survey 2022

2.2.2. Orphan market exclusivity extension

In 2022, four orphan medicinal products benefited from a two-year extension of their respective market exclusivity:

- Livmarli (maralixibat chloride) for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 2 months of age and older;
- Nulibry (fosdenopterin) for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A;
- Voraxaze (glucarpidase) to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity;
- Zokinvy (lonafarnib) for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of Hutchinson-Gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous LMNA mutation with progerin-like protein accumulation or a homozygous or compound heterozygous ZMPSTE24 mutation.

2.3. Paediatric use marketing authorisation

No paediatric use marketing authorisation (PUMA) was granted in 2022.

2.4. Placing on the market

The "Register of deadlines to put a medicinal product on the market" (Article 33 of the Paediatric Regulation) lists the two-year timelines by which marketing authorisation holders (MAHs) have to place their medicinal products on the market following completion of an agreed PIP and obtaining a paediatric indication. The register includes information on the fulfilment of this requirement provided by NCAs and MAHs until the end of 2022.

3. Failure to comply with the obligations set out in the Paediatric Regulation

3.1. Submission of PIP and waiver applications to the PDCO

Article 16 of the Paediatric Regulation requires pharmaceutical companies to submit applications for

a PIP and a waiver no later than upon completion of the human pharmacokinetic (PK) studies in adults specified in Section 5.2.3 of Part I of Annex I to Directive 2001/83/EC, except when duly justified.

Late submissions are being reported since 2010 (Table 2) for applications with a delay greater than six months. From 2014 only those considered by the PDCO as not justified are being reported.

Table 2. – Number of procedures with a time lag six months or longer between completion of adult PK studies and submission of PIP or waiver application

Procedure type	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
PIPs (% of total granted)	44 (59%)	34 (39%)	18 (20%)	12 (13%)	7 (10%)	20 (23%)	24 (28%)	9 (16%)	26 (25%)	38 (26%)	31 (22%)	43 (33.3%)
Full waivers (% of total granted)	13 (42%)	11 (23%)	6 (11%)	4 (8%)	4 (8%)	14 (27%)	14 (16%)	9 (20%)	25 (25%)	26 (24%)	23 (20%)	37 (32.7%)

Source: EMA Paediatric database

In 2022, a total of 129 PIPs received a positive opinion and 113 full product-specific waivers were granted by the PDCO.

The list of unjustified late submissions of PIP and waiver applications is presented in Annex I.

3.2. Completion of PIPs

The EMA decisions on PDCO opinions contain the expected date of PIP completion.

For the analysis of timely completion, the PIPs with an expected completion date until 30 June 2022 were reviewed. This cut-off date was chosen to account for the fact that applicants must submit the completed study reports within six months of completion (Art. 46) and studies (and PIPs) completed after June 2022 may not have yet been subjected to a final compliance check.

In total, 575 PIPs were scheduled to finish by 30 June 2022 of those, 305 (53%) were completed; of the remaining 270 that have not been completed, 156 were discontinued or a full waiver was granted in subsequent modification. For 33 PIPs a valid justification for the delayed completion has not been provided or found (e.g. a modification to amend the date of completion is pending/ongoing or development has been discontinued), these are listed in Annex II.

3.3. Annual reports on deferrals

According to Article 34.4 of the Paediatric Regulation, MAHs should submit an annual report to the Agency providing an update on progress of deferred paediatric studies in accordance with the

EMA decision agreeing the PIP and granting a deferral. In 2022 the EMA received 332 annual reports on deferred measures. All MAHs except one submitted their annual report on deferred measures due in 2022.

The list of companies that did not submit one or more annual reports since 2011 is included in Table 3.

Table 3. List of companies not submitting annual reports on deferred measures in due time

Company	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
Aastrom Biosciences DK Aps					1							
Actelion Registration Ltd						1	1					
Aegerion Pharmaceuticals						1	1					
AMAG Pharmaceuticals, Inc.					1		1	1				
Amgen Europe B.V.			1									
APEIRON Biologics AG								1				
Clinigen Healthcare Ltd						1						
Clinuvel (UK) Limited					1							
Eisai Ltd.	1					1						
Forest Laboratories Limited				1	1							
Genzyme Europe B.V.	1											
GlaxoSmithKline	1											
Ipsen Pharma								1				
Janssen-Cilag International N.V.	1				1							
Kowa Pharmaceutical Europe CompanyLtd	1	1	4									
Merck Sharp & Dohme (Europe) Inc.	2	1	2									
Novartis (Europharm Limited, Vaccinesand diagnostics)		2	1									
Novo Nordisk A/S	1	1	2									
N.V. Organon						1						
Nycomed Danmark ApS						1						
Omrix Biopharmaceuticals SA			1		1							
Pfizer Limited	2											

Pharmaxis Pharmaceuticals Limited					1							
Roche Registration Limited	1	1	1		1							1
Seqirus S.r.l.						1						
Sigma-Tau SpA		1	1		1							
Takeda Global Research and Dev.Centre (Europe) Ltd		1			1							
Teva Pharma GmbH						1						
Theravance, Inc.		1	1									
Total p/a:	11	9	14	1	11	8	3	3	0	0	0	1

Source: EMA database (PedRA)

Annex I. List of non-justified late submissions of applications for PIPs or waivers

This list includes only applications for which a decision on a PIP or a waiver was adopted by the European Medicines Agency in 2022.

The below table shows the agreed PIPs or waivers submitted in 2022 with a significant delay of at least 6 months for which none or unacceptable (by the PDCO) justification was provided. The timing of submission should not be later than the end of healthy subject or patient PK, which can coincide with the initial tolerability studies, or the initiation of the adult phase II studies (proof-of-concept studies). In cases where a phase II study in adults is already completed by the time of the PIP submission, the submission is in principle considered delayed unless justified.

The number of months of delay is calculated from the date of the completion of PK studies in adults or the initiation of adult phase II studies as declared by the applicant in the application for a PIP or a product-specific waiver request.

Further information on the timing of a PIP application can be found on the EMA website (Q 1.1).

Company	**Substance** (INN as applicable)	**Application type**
AbbVie Ltd	adalimumab conjugated with (4S)-4-[2-(2-bromoacetamido)acetamido]-5-{3-[(4-{(4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-4a,6a-dimethyl-2-oxo-6b-[(phosphonooxy)acetyl]-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H,8H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8-yl}phenyl)methyl] anilino}-5-oxopentanoic acid; ABBV-154	Waiver
Adamed Pharma S.A.	rosuvastatin (Calcium) / telmisartan	Waiver
Adamed Pharma S.A.	tadalafil / finasteride	Waiver
Adamed Pharma S.A.	hydrochlorothiazide / amlodipine / candesartan cilexetil	Waiver
ADC Therapeutics SA	camidanlumab tesirine	PIP
Advenchen Laboratories, LLC	catequentinib	PIP
Akero Therapeutics, Inc.	efruxifermin	PIP
AlloVir International DAC	posoleucel	PIP
Arena Pharmaceuticals, Inc.	etrasimod L-arginine	PIP
AstraZeneca AB	oleclumab	Waiver
AstraZeneca AB	monalizumab	Waiver

AstraZeneca AB	eplontersen	Waiver
Biocodex SA	stiripentol	PIP
Biohaven Pharmaceutical Ireland DAC	troriluzole (hydrochloride)	PIP
BIOKOSMOS S.A.	fluorine (18F) PSMA-1007	Waiver
Blueprint Medicines (Netherlands) B.V.	2-{4-[4-(4-{5-[(1S)-1-amino-1-(4-fluorophenyl) ethyl]pyrimidin-2-yl}piperazin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]-1H-pyrazol-1-yl}ethan-1-ol	Waiver
Boehringer Ingelheim International GmbH	peptide derivative of glucagon-like-peptide 1 and glucagon with fatty acid side chain	PIP
Calliditas Therapeutics France SAS	setanaxib	Waiver
Clene Netherlands B.V.	gold (Au)	Waiver
Cogent Biosciences, Inc	3,4-dimethyl-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazole-5-carboxamide	Waiver
Deciphera Pharmaceuticals	vimseltinib	Waiver
Desitin Arzneimittel GmbH	sirolimus	PIP
EigerBio Europe Limited	avexitide (acetate)	Waiver
EigerBio Europe Limited	lonafarnib	PIP
EigerBio Europe Limited	avexitide (acetate)	PIP
Eli Lilly and Company Limited	sintilimab	Waiver
EQRx Inc.	sugemalimab	Waiver
FibroGen, Inc.	pamrevlumab	PIP
G1 Therapeutics, Inc.	trilaciclib (dihydrochloride)	Waiver
Galderma International S.A.S.	botulinum toxin type A	Waiver
Gilead Sciences International Ltd.	sacituzumab govitecan	Waiver
GlaxoSmithKline Trading Services Limited	cobolimab	Waiver
Global Blood Therapeutics Netherlands B.V.	inclacumab	PIP
Helsinn Birex Pharmaceuticals Ltd.	infigratinib	Waiver

Horizon Therapeutics Ireland DAC	2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indan-2-carboxylic acid	Waiver
Immunovant Sciences, GmbH	batoclimab	PIP
Incyte Biosciences Distribution B.V.	parsaclisib (hydrochloride)	Waiver
Incyte Biosciences Distribution B.V.	pemigatinib	Waiver
Incyte Biosciences Distribution B.V.	ruxolitinib (phosphate)	PIP
Incyte Biosciences Distribution B.V.	retifanlimab	Waiver
Inmunotek S.L.	whole-cell heat-inactivated bacterial strains of Escherichia coli, Klebsiella pneumoniae, Proteus vulgaris and Enterococcus faecalis	PIP
Innate Pharma SA	lacutamab	Waiver
IntraBio Ltd.	acetyl-L-leucine ((s)-(acetylamino)-4-methylpentanoic acid) (IB1001)	PIP
Invex Therapeutics Ltd	exenatide (acetate)	PIP
Ionis Pharmaceuticals	2'-O-(2'-methoxyethyl) modified antisense oligonucleotide targeting prekallikrein mRNA (ISIS 721744)	PIP
Iperboreal Pharma Srl	L-carnitine/glucose/calcium chloride dihydrate/magnesium chloride hexahydrate/sodium lactate/sodium chloride	PIP
Janssen-Cilag International NV	RSV preF protein	PIP
Jazz Pharmaceuticals Ireland Ltd	suvecaltamide (hydrochloride)	Waiver
Krka, d.d., Novo mesto	hydrochlorothiazide / amlodipine / telmisartan	Waiver
Krystal Biotech, Inc.	beremagene geperpavec	PIP
Lumos Pharma, Inc.	ibutamoren mesylate	PIP
Madrigal Pharmaceuticals EU Limited	resmetirom	PIP
Merck Healthcare KGaA	xevinapant	Waiver
Merck Sharp & Dohme (Europe), Inc.	live, attenuated, dengue virus, serotype 4 (DENV4) / live, attenuated,	PIP

	dengue virus, serotype 3 (DENV3) / live, attenuated, chimeric dengue virus, serotype 2 (DENV2) / live, attenuated, dengue virus, serotype 1 (DENV1)	
Mitsubishi Tanabe Pharma GmbH	dersimelagon	PIP
Novartis Europharm Limited	anti-TGFbeta fully human monoclonal antibody (NIS793)	Waiver
Novartis Europharm Limited	1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one	Waiver
Novo Nordisk A/S	ziltivekimab	Waiver
NS Pharma, Inc.	viltolarsen	PIP
Orchard Therapeutics (Netherlands) B.V.	autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) genetically modified with the lentiviral vector IDUA LV, encoding for the human α-L-iduronidase (IDUA) gene (OTL-203)	PIP
Orphinic Scientific Bis Sp. z o.o.	magnesium lactate dihydrate / tramadol (hydrochloride)	Waiver
OSE Immunotherapeutics	peptide KLBPVQLWV / peptide SMPPPGTRV / peptide YLQLVFGIEV / peptide RLLQETELV / peptide YLSGADLNL / peptide LLTFWNPPV / Peptide IMIGHLVGV / peptide KVAEIVHFL / peptide KVFGSLAFV / Pan HLA DR-binding epitope D-Ala-Lys-Cha-Val-Ala-Ala-Trp-Thr-Leu-Lys-Ala-Ala-D-Ala (OSE2101)	Waiver
OT4B	oxytocin	PIP
Otsuka Pharmaceutical Netherlands B.V.	cedazuridine / decitabine	PIP
Pharma Mar, S.A.	lurbinectedin	Waiver
Prilenia Therapeutics B.V.	pridopidine (hydrochloride)	PIP
Reata Ireland Limited	omaveloxolone	PIP
Roche Registration GmbH	ralmitaront	PIP
Roche Registration GmbH	obinutuzumab	PIP

ROXALL Medizin GmbH	freeze-dried allergen extract of Betula pendula pollen	PIP
Sanofi-Aventis Groupe	dupilumab	PIP
UCB Pharma SA.	alprazolam	PIP
Urovant Sciences GmbH	vibegron	PIP
Vanessa Research Magyarorszag Kft/Vanessa Research Hungary ltd	zinc gluconate / alisitol / retinyl palmitate	PIP
VectivBio AG	apraglutide	PIP
Verisfield Single Member S.A.	yanocobalamin / pyridoxine (hydrochloride) / thiamine (hydrochloride) / diclofenac (potassium)	Waiver
Verisfield Single Member S.A.	cyanocobalamin / pyridoxine hydrochloride / thiamine hydrochloride / diclofenac sodium	Waiver
ViiV Healthcare UK Limited	dolutegravir / HIV-1 maturation inhibitor (GSK3640254)	PIP
ViiV Healthcare UK Limited	HIV-1 maturation inhibitor (GSK3640254)	PIP
Y-mAbs Therapeutics A/S	naxitamab	PIP

Source: EMA database PedRA

Annex II. List of PIPs not completed by the agreed date until 30 June 2022

It should be noted that this list does not specify if the development of the medicinal product has been discontinued or not, as the EMA may not have been informed by the company accordingly.

The following list includes all PIPs due to be completed by 30 June 2022 without sufficient justification for the delay.

Procedure number	**Substance**	**Invented Name**	**Company**
EMEA-002266-PIP01-17	recombinant human acid ceramidase	N/A	Aceragen Inc.
EMEA-000488-PIP02-11	rubidium-82	Cardiogen-82	Advanced Accelerator Applications
EMEA-001134-PIP01-11	chimeric monoclonal anti-shiga toxin (Stx) antibodies Cαstx1 and Cαstx2	Shigamabs	Albany Regulatory Consulting Limited
EMEA-000337-PIP01-08	grass pollen preparation	N/A	Allergopharma J. Ganzer KG
EMEA-000284-PIP01-08-M04	modified grass pollen extract	N/A	Allergy Therapeutics (UK) Limited
EMEA-000814-PIP01-09	birch/alder/hazel pollen Extract	POLLINEX Quattro 1.0 mL Birch/Alder/Hazel	Allergy Therapeutics (UK) Ltd
EMEA-000988-PIP01-10	ciclosporin	N/A	APT Pharmaceuticals Inc
EMEA-001369-PIP01-12	exon 45 specific phosphorothioate oligonucleotide	N/A	Biomarin InternationalLimited
EMEA-001374-PIP01-12	exon 53 specific phosphorothioate oligonucleotide’	N/A	BioMarin InternationalLimited
EMEA-001267-PIP01-12	[N-{4-Chloro-2-[(1-oxido-4-pyridinyl)carbonyl]phenyl}-4-(1,1-dimethylethyl) benzenesulfonamide, sodium salt	N/A	ChemoCentryx, Inc.

EMEA-001513-PIP01-13	estetrol / levonorgestrel	N/A	Estetra S.A.
EMEA-000786-PIP01-09-M02	autologous CD34+ cells transduced with lentiviral vector containing the human Wiskott Aldrich Syndrom Protein gene	N/A	Genethon
EMEA-001175-PIP01-11-M04	albiglutide	Eperzan	Glaxo Group Limited
EMEA-000532-PIP01-09	sodium bituminosulphonate / clindamycin phosphate	IchthoseptalN	Ichthyol -Gesellschaft Cordes, Hermanni & Co. (GmbH & Co.) Kg
EMEA-000580-PIP01-09	dalcetrapib	N/A	Roche Registration Limited
EMEA-000976-PIP01-10	grass pollen allergen extract from Cocksfoot (Dactylis glomerata L.)/ Sweet vernal grass (Anthoxanthum odoratum L.)/ Rye grass (Lolium perenne L.)/ Meadowgrass (Poa pratensis L.)/ Timothy (Phleum pratense L.)	Staloral 5 Grasses	Stallergenes S.A.
EMEA-000977-PIP01-10	house dust mites allergen extract from Dermatophagoides pteronyssinus and Dermatophagoides farinae (50/50)	STALORAL Mites	STALLERGENES S.A.
EMEA-001568-PIP03-14	ceftriaxone / sulbactam	Elores	Venus Pharma GmbH
EMEA-000487-PIP01-08	bromocriptine	Cycloset	Veroscience Eu Ltd
EMEA-000044-PIP01-07	TGplPTH1-34	N/A	Kuros Biosurgery International AG
EMEA-000651-PIP01-09-M02	Cholic acid	N/A	FGK Representative Service GmbH

EMEA-000341-PIP02-09-M05	L-asparaginase encapsulated in erythrocytes	GRASPA	ERYTECH pharma S.A.
EMEA-000487-PIP01-08	bromocriptine mesilate	Cycloset	VeroScience EU Ltd
EMEA-000362-PIP01-08-M04	Aliskiren hemifumarate	Rasilez	IQVIA RDS France
EMEA-000810-PIP01-09	12 Grass Pollen Extract, Cultivated Rye Pollen Extract and Birch Pollen Extract	POLLINEX Quattro 1.0 mL Grasses/Rye and Birch (50%:50%)	Allergy Therapeutics (UK) Ltd
EMEA-000811-PIP01-09	12 Grass Pollen Extract, Cultivated Rye Pollen Extract and Mugwort Pollen Extract	POLLINEX Quattro 1.0 mL Grasses/Rye and Mugwort (50%:50%)	Allergy Therapeutics (UK) Ltd
EMEA-000812-PIP01-09	12 Grass Pollen Extract, Cultivated Rye Pollen Extract and Birch/Alder/Hazel Pollen Extract	POLLINEX Quattro 1.0 mL Grasses/Rye and Birch/Alder/Hazel (50%:50%)	Allergy Therapeutics (UK) Ltd
EMEA-000880-PIP02-11-M04	Sonidegib	Odomzo	Sun Pharmaceutical Industries Europe B.V.
EMEA-000898-PIP01-10-M02	Meropenem	Not available	NeoMero Consortium
EMEA-001226-PIP01-11-M01	Surotomycin	N/A	Cubist (UK) Ltd.
EMEA-001413-PIP01-13	Allergoid preparation of Phleum pratense pollen extract	Allergovit Phleum	Allergopharma GmbH & Co. KG
EMEA-001909-PIP01-15	Cathine hydrochloride (D-Norpseudoephedrine hydrochloride)	ALVALIN RIEMSER, 40 mg/g, Tropfen zum Einnehmen, Lösung	Schuck GmbH
EMEA-002051-PIP02-16	allopregnanolone	N/A	Sage Therapeutics Inc